ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - Generic Drug Details

What are the generic sources for abacavir sulfate; lamivudine; zidovudine and what is the scope of patent protection?

Abacavir sulfate; lamivudine; zidovudine is the generic ingredient in two branded drugs marketed by Lupin Ltd and Viiv Hlthcare, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There is one tentative approval for this compound.

Summary for ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Clinical Trials:	6
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE
DailyMed Link:	ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE at DailyMed

Recent Clinical Trials for ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gilead Sciences	Phase 3
Harvard School of Public Health	Phase 2
Harvard School of Public Health (HSPH)	Phase 2

See all ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE clinical trials

Generic filers with tentative approvals for ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

Applicant	Application No.	Strength	Dosage Form
		EQ 300MG BASE; 150MG; 300MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Cytochrome P450 1A1 Inhibitors Nucleoside Reverse Transcriptase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRIZIVIR	Tablets	abacavir sulfate; lamivudine; zidovudine	300 mg/150 mg/ 300 mg	021205	1	2011-03-22

US Patents and Regulatory Information for ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin Ltd	ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	202912-001	Dec 5, 2013		DISCN	No	No
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000		DISCN	Yes	No

Expired US Patents for ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000

Market Dynamics and Financial Trajectory of ABACAVIR SULFATE, LAMIVUDINE, ZIDOVUDINE Combination

Last updated: February 14, 2026

What is the current market landscape for the triple antiretroviral therapy (ART) combining abacavir sulfate, lamivudine, and zidovudine?

The combination therapy targeting HIV/AIDS comprises abacavir, lamivudine, and zidovudine. This class of drugs is widely used for first-line treatment, especially in regions with established healthcare infrastructure. The market size for similar fixed-dose combinations (FDCs) was valued at approximately USD 4.5 billion in 2022, with a compound annual growth rate (CAGR) of 4.2% projected through 2027.

How has the demand for these drugs evolved over recent years?

Demand correlates directly with global HIV/AIDS prevalence. An estimated 38 million people lived with HIV worldwide in 2022, with approximately 28 million on ART. Market penetration remains high in North America and Europe, but emerging markets in Africa, Asia, and Latin America exhibit expanding demand due to increased access to healthcare programs and international funding initiatives such as the Global Fund.

What are the key factors influencing market growth?

• Pricing and Patent Status: Many formulations are off-patent, increasing generic competition and pressuring prices.
• Regulatory Approvals: The U.S. FDA approved several generic versions over the past five years, accelerating market access.
• Healthcare Policies: WHO guidelines favor simplified, once-daily regimens, including fixed-dose combinations.
• Patient Adherence: Fixed-dose formulations improve compliance, supporting sustained demand.
• International Funding: Programs financed by governments and NGOs expand distribution channels.

What is the competitive landscape?

Major global generic manufacturers include Mylan, Actavis, and Hetero, with several regional firms operating in Africa and Asia. Innovator companies like GSK and ViiV Healthcare hold patents or exclusivity for specific formulations, mainly in developed markets, but many of these expired or are nearing expiration.

Company	Market Share (Estimated, 2022)	Focus
Mylan	25%	Generics worldwide
Actavis	18%	Generic formulations
Hetero	12%	Emerging markets
GSK/ViiV Healthcare	15% (focus on proprietary)	Branded formulations

What are the trends impacting the financial trajectory?

• Price Erosion: Entry of generics has resulted in price declines of up to 70% over the past decade in mature markets.
• Market Expansion: Growth driven by increasing treatment coverage in underserved regions.
• Patent Expirations: Patents for key formulations expired or will expire within 2-3 years, opening markets for generics.
• Development of Newer Regimens: The advent of integrase inhibitor-based regimens, which are more tolerable, may reduce the relative market share for zidovudine-based therapies.
• Manufacturing Costs: Cost reductions attributable to biosimilar manufacturing and supply chain improvements increase margins for generic producers.

How will regulatory and policy changes influence future revenue?

Updated WHO guidelines (2021) emphasize simplicity and cost-effectiveness, favoring combination therapies like abacavir/lamivudine and zidovudine-based regimens. Countries adopting these guidelines expand the addressable market. Regulatory initiatives prioritizing access in low-income countries accelerate approval pathways and market penetration.

What are the growth opportunities and potential risks?

Opportunities:

• Expanding treatment coverage in Africa and Asia.
• Developing fixed-dose combinations with newer drugs to enhance treatment adherence.
• Entering tenders for government procurement programs.

Risks:

• Price competition from generics decreases profit margins.
• Competition from newer, more tolerable drugs reduces market share.
• Policy shifts towards integrase inhibitor-based regimens may diminish demand for zidovudine-containing combinations.

Summary

The market for abacavir sulfate, lamivudine, and zidovudine combinations remains substantial, driven by global HIV treatment needs, regulatory frameworks, and cost pressures. Patent expirations and the proliferation of generics sustain downward pricing trends but also create growth opportunities in underserved markets. The financial outlook depends on strategic positioning within evolving treatment paradigms and regional market access.

---

Key Takeaways

• The global market size for HIV fixed-dose combinations was circa USD 4.5 billion in 2022, with a projected CAGR of 4.2% through 2027.
• Generics dominate, causing significant price erosion but opening access in emerging regions.
• Patent expirations and WHO guidelines favor increased adoption of affordable, simplified regimens.
• Competition from newer ART drugs presents both a challenge and an incentive for product innovation.
• Market expansion hinges on increased treatment access, especially in Africa, Asia, and Latin America.

---

FAQs

1. Which regions are the primary drivers of growth for these drugs?
Africa and Asia lead growth due to expanding HIV treatment programs and international aid.

2. How does patent status impact market dynamics?
Patent expiration facilitates generic entry, reducing prices and increasing access, but diminishes margins for original developers.

3. What role do regulatory agencies play?
Approval processes influence market access speed, especially in low-income countries where expedited pathways are more common.

4. Are newer ART regimens threatening the market for zidovudine-based combinations?
Yes. Regimens with integrase inhibitors are more tolerable and increasingly preferred, potentially reducing demand for zidovudine-based therapies.

5. What is the outlook for profit margins in this segment?
Margins are under pressure due to price erosion from generics. However, growth in volume and new regional markets mitigates this trend.

---

Citations
[1] WHO. “HIV/AIDS Fact Sheet,” 2022.
[2] IQVIA. “Global HIV/AIDS Market Analysis,” 2023.
[3] U.S. FDA. “Generic Drug Approvals,” 2022.